Australia markets open in 2 hours 50 minutes

Pharmaxis Ltd (PMXSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0650-0.0134 (-17.09%)
At close: 10:56AM EDT
Full screen
Loading interactive chart…
  • PR Newswire

    Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

    Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at three dosage levels.

  • PR Newswire

    Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

    Pharmaxis (ASX: PXS) today announced that its novel topical drug treatment for scarring has delivered positive Phase 1 clinical trial results and will now advance to the next stage of development in patients. In a study of healthy volunteers led by renowned surgeon Prof Fiona Wood AM the Pharmaxis drug demonstrated good tolerability and full inhibition of the enzymes being targeted to prevent scarring.

  • PR Newswire

    Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

    Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.